Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling. Issue 5 (May 2016)

• Record Type: Journal Article
• Authors: Gao, Yuansheng
• Is Part Of: Journal of cardiovascular pharmacology. Volume 67:Issue 5(2016)
• Publication Date: 2016-05
• Subjects: nitric oxide -- soluble guanylyl cyclase -- cGMP -- cIMP -- hypoxic vasoconstriction; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000000330
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Abstract: Soluble guanylyl cyclase (sGC) is the principal enzyme in mediating the biological actions of nitric oxide. On activation, sGC converts guanosine triphosphate to guanosine 3′, 5′-cyclic monophosphate (cGMP), which mediates diverse physiological processes including vasodilation, platelet aggregation, and myocardial functions predominantly by acting on cGMP-dependent protein kinases. Cyclic GMP has long been considered as the sole second messenger for sGC action. However, emerging evidence suggests that, in addition to cGMP, other nucleoside 3′, 5′-cyclic monophosphates (cNMPs) are synthesized by sGC in response to nitric oxide stimulation, and some of these nucleoside 3′, 5′-cyclic monophosphates are involved in various physiological activities. For example, inosine 3′, 5′-cyclic monophosphate synthesized by sGC may play a critical role in hypoxic augmentation of vasoconstriction. The involvement of cytidine 3′, 5′-cyclic monophosphate and uridine 3′, 5′-cyclic monophosphate in certain cardiovascular activities is also implicated.